thefederalregister.org Federal Register Research Archive

Document

Hospira, Inc., et al.; Withdrawal of Approval of 12 Abbreviated New Drug Applications

The Food and Drug Administration (FDA or Agency) is withdrawing approval of 12 abbreviated new drug applications (ANDAs) from multiple applicants. The applicants notified the Ag...

PDF versionSource Record
Department of Health and Human Services
Food and Drug Administration
  1. [Docket No. FDA-2019-N-0163]

AGENCY:

Food and Drug Administration, HHS.

ACTION:

Notice.

SUMMARY:

The Food and Drug Administration (FDA or Agency) is withdrawing approval of 12 abbreviated new drug applications (ANDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.

DATES:

Approval is withdrawn as of March 14, 2019.

FOR FURTHER INFORMATION CONTACT:

Trang Tran, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 75, Rm. 1671, Silver Spring, MD 20993-0002, 240-402-7945, .

SUPPLEMENTARY INFORMATION:

The applicants listed in the table have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications under the process described in § 314.150(c) (21 CFR 314.150(c)). The applicants have also, by their requests, waived their opportunity for a hearing. Withdrawal of approval of an application or abbreviated application under § 314.150(c) is without prejudice to refiling.

Application No. Drug Applicant
ANDA 065343 Epirubicin Hydrochloride (HCl) Injection USP, 10 milligrams (mg)/5 milliliters (mL), 50 mg/25 mL, 150 mg/75 mL, and 200 mg/100 mL Hospira, Inc., 275 North Field Dr., Bldg. H1, Lake Forest, IL 60045.
ANDA 070562 Flurazepam HCl Capsules USP, 15 mg Pharmaceutical Basics, Inc., 301 South Cherokee St., Denver, CO 80223.
ANDA 070563 Flurazepam HCl Capsules USP, 30 mg Do.
ANDA 071808 Flurazepam HCl Capsules USP, 15 mg Halsey Drug Co., Inc., 1827 Pacific St., Brooklyn, NY 11233.
ANDA 071809 Flurazepam HCl Capsules USP, 30 mg Do.
ANDA 076827 Vinorelbine Injection USP, Equivalent to 10 mg base/mL Hospira, Inc.
ANDA 077736 Polyethylene Glycol 3350 Powder for Oral Solution, 17 grams/scoopful Breckenridge Pharmaceutical, Inc., 6111 Broken Sound Parkway NW, Suite 170, Boca Raton, FL 33487.
ANDA 085763 Glutethimide Tablets, 500 mg Chelsea Laboratories, Inc., 896 Orlando Ave., West Hampstead, NY 11552.
ANDA 085791 Pentobarbital Sodium Capsules, 100 mg Do.
ANDA 087297 Glutethimide Tablets, 500 mg Phoenix Pharmaceuticals, Inc., 111 Leuning St., South Hackensack, NJ 07606.
ANDA 088819 Aristocort A (triamcinolone acetonide) Cream, 0.1% Astellas Pharma U.S., Inc., Three Parkway North, Deerfield, IL 60015.
ANDA 089459 Glutethimide Tablets, 500 mg Halsey Drug Co., Inc.
( printed page 3468)

Therefore, approval of the applications listed in the table and all amendments and supplements thereto, are hereby withdrawn as of March 14, 2019. Introduction or delivery for introduction into interstate commerce of products without approved new drug applications violates section 301(a) and (d) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331(a) and (d)). Drug products that are listed in the table that are in inventory on March 14, 2019 may continue to be dispensed until the inventories have been depleted or the drug products have reached their expiration dates or otherwise become violative, whichever occurs first.

Dated: February 7, 2019.

Lowell J. Schiller,

Acting Associate Commissioner for Policy.

[FR Doc. 2019-02032 Filed 2-11-19; 8:45 am]

BILLING CODE 4164-01-P

Legal Citation

Federal Register Citation

Use this for formal legal and research references to the published document.

84 FR 3467

Web Citation

Suggested Web Citation

Use this when citing the archival web version of the document.

“Hospira, Inc., et al.; Withdrawal of Approval of 12 Abbreviated New Drug Applications,” thefederalregister.org (February 12, 2019), https://thefederalregister.org/documents/2019-02032/hospira-inc-et-al-withdrawal-of-approval-of-12-abbreviated-new-drug-applications.